Regulatory authorities in Hong Kong are escalating their oversight of the quality of initial public offering (IPO) documents as the market continues to refine its listing mechanisms. Following a circular from the Securities and Futures Commission (SFC) in late January highlighting serious deficiencies in the preparation of listing documents and setting a 300-page guideline limit for prospectuses, the Hong Kong Exchanges and Clearing Limited (HKEX) is now further refining its review standards to directly address market malpractices. Senior HKEX executives have recently publicly criticized prevalent issues in Hong Kong IPO prospectuses, including exaggerated marketing, content padding, and inaccurate industry rankings. Simultaneously, they have issued guidelines to address shortcomings in the listing review process for biotech companies, aiming to comprehensively reinforce the responsibilities of listing applicants and sponsors, accelerate the listing of high-quality enterprises, and cleanse the IPO market ecosystem.

Liu Ying, Managing Director and Co-Head of IPO Vetting at HKEX, stated publicly that while most recent listing applications have formally complied with the 300-page limit since the SFC's guideline took effect, new problems of "countermeasures to circumvent policies" have emerged. Many companies and their sponsors have not used the condensed format to focus on disclosing core information. Instead, they have fallen into the trap of prioritizing marketing over substance, heavily using exaggerated advertising terminology to package their prospectuses. This turns what should be rigorous and objective disclosure documents into vehicles for brand promotion, severely impacting IPO review efficiency and the authenticity of information disclosure.

Typical cases identified during HKEX reviews reveal serious content imbalance in some prospectuses. In certain instances, the first five pages of a prospectus are entirely devoted to brand promotion and value packaging, with no effective introduction to the company's core business, operating model, or competitive advantages—key information for listing. This misplaced content arrangement significantly increases review difficulty. Furthermore, false industry rankings have become another prominent malpractice. To embellish their operational strengths, many applicants deliberately define extremely narrow geographical scopes, split product categories into minute segments, or adopt self-defined market segmentation standards to arbitrarily claim they are "industry number one" or hold a "market-leading position." Such ranking data often suffers from vague statistical bases, overly narrow sample coverage, and opaque definition standards, failing to fully disclose the statistical methodology and applicability of the rankings to investors, which can easily mislead the market and investors.

In response to these industry malpractices, HKEX has clearly sounded a regulatory alarm, emphasizing that any statements in a prospectus regarding industry rankings or market position must have clear and compliant statistical support. If there are flaws in data sources, definition methods, or sample scope, failing to fully fulfill information disclosure obligations will directly constitute misleading statements. The regulatory body also reminds all listing applicants and sponsors to adhere to principles of prudence and rigor when drafting prospectuses and citing third-party industry reports and market data, strictly avoiding violations such as deliberate embellishment and false advertising, and upholding the core bottom line of truth, accuracy, and completeness in listing documents.

Liu Ying emphasized that the SFC's core intent in setting the 300-page limit was to compel the industry to streamline document structure, strip out ineffective and redundant content, and guide companies to focus on precise disclosure of key information regarding operations, finances, and risks. It was not to create space for exaggerated marketing or repetitive, hollow promotional content. The core demand of Hong Kong's regulators is to steer listing documents back to the essence of information disclosure, abandoning excessive packaging and ineffective padding, so investors can clearly, intuitively, and comprehensively understand a company's true operating condition. To this end, HKEX expects all sponsoring institutions and prospective listing companies to strictly align with regulatory requirements from the initial draft stage of the prospectus, accurately organize core disclosure information, improve the quality of listing application materials from the source, reduce subsequent rounds of supplementary documentation and revisions during the review process, and tangibly enhance overall IPO review efficiency.

Addressing Specific Biotech Sector Challenges

Beyond general IPO prospectus issues, HKEX also specifically highlighted pain points in the listing review for biotech companies under Chapter 18A of the Listing Rules. As a distinctive listing channel in Hong Kong, Chapter 18A provides a pathway to listing for pre-revenue biotech companies. However, many biotech firms currently submit insufficiently prepared and unprofessional listing application materials, becoming a major obstacle to speeding up reviews. According to reports, when reviewing biotech listing applications, HKEX often needs to repeatedly request detailed core clinical trial data from applicants, covering overall trial design, participant enrollment criteria, core safety and efficacy data, and scientific rationale. Most companies have not completed the organization of complete clinical data or established a scientific justification system before submitting their applications, leading to a significant increase in the frequency of review inquiries and responses, prolonging listing timelines, and severely impacting IPO progress efficiency.

Based on the current review situation, HKEX has provided clear industry optimization guidance. It recommends that all biotech companies planning to list in Hong Kong via the Chapter 18A channel complete the organization of a full set of clinical trial data packages and establish a robust internal scientific justification system during the early preparation stages of their listing application. This ensures that submitted listing materials are data-rich, logically complete, and compliant, precisely matching regulatory review requirements to minimize the review cycle and maximize the chances of a successful listing.

Overall Regulatory Direction and Market Impact

Overall, this concentrated statement from HKEX represents a significant move to improve the quality and efficiency of Hong Kong IPO regulation, marking a comprehensive upgrade of the listing review process from mere "compliance attainment" to "quality pursuit and excellence." Liu Ying stated that Hong Kong regulators hope the entire industry will reshape its mindset regarding listing preparation, abandoning a侥幸 mentality that prioritizes packaging over substance, and instead adopt a扎实, rigorous, and truth-seeking approach throughout the prospectus drafting and listing material preparation process. For prospective listing companies and their sponsors, only by strictly aligning with the new regulatory rules, cutting无效 marketing content, solidifying core information disclosure, and addressing专业资料 shortcomings can they adapt to Hong Kong's latest review standards, achieve efficient IPO process推进, further夯实 the quality of information disclosure in the Hong Kong market, maintain公开透明的 operating order in the capital market, and better protect the legitimate rights and interests of广大 investors.